RNS Number : 8038D
RTW Venture Fund Limited
02 November 2020
2 November 2020
RTW VENTURE FUND LIMITED
(the "Company")
TOTAL VOTING RIGHTS
In accordance with DTR 5.6.1R, as at 31 October 2020 the Company had
187,833,366 Ordinary Shares in issue, each with equal voting rights, and no shares held in Treasury.
This total voting rights figure can be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.
For further information, please contact:
|
RTW Investments, LP
Stephanie Sirota, Chief Business Officer
Alexandra Taracanova, PhD, Director of Investor Relations
Julia Enright, Business Development Associate
Ocorian Administration (Guernsey) Limited
Kevin Smith
|
+1 (646) 343 9280
+44 (0) 1481 742 642
|
|
J.P. Morgan Cazenove
William Simmonds
James Bouverat (Sales)
Barclays
Tom Swerling
Andrew Tusa
|
+44 (0)20 7742 4000
+44 (0)20 7623 2323
|
About RTW Venture Fund Limited:
RTW Venture Fund Limited (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.
RTW Venture Fund Limited is managed by RTW Investments, LP, a leading US healthcare investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.
Visit the RTW website at
www.rtwfunds.com
for more information.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END
TVREADEEDADEFFA
|
